Alyeska Investment Group L.P. Sells 292,712 Shares of Ventas, Inc. $VTR

Key Points

• Alyeska Investment Group cut its Ventas stake by 60.9% in the second quarter, selling 292,712 shares and retaining 188,054 shares valued at approximately $16.7 million.
• Ventas reported quarterly EPS of $0.97, exceeding estimates by $0.01, while revenue rose 21.7% year over year to $1.73 billion. Institutional investors own 94.18% of the healthcare REIT.
• Analysts maintain a generally positive view, giving Ventas a consensus “Moderate Buy” rating and an average price target of $98.17, compared with a recent share price of $91.18.

Alyeska Investment Group L.P. decreased its stake in Ventas, Inc. (NYSE:VTR - Free Report) by 60.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,054 shares of the real estate investment trust's stock after selling 292,712 shares during the quarter. Alyeska Investment Group L.P.'s holdings in Ventas were worth $16,699,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of VTR. BlackRock Inc. bought a new position in Ventas during the 2nd quarter valued at about $4,953,439,000. State Street Corp grew its stake in Ventas by 2.5% during the fourth quarter. State Street Corp now owns 29,662,635 shares of the real estate investment trust's stock worth $2,309,234,000 after buying an additional 735,620 shares during the last quarter. Geode Capital Management LLC grew its stake in Ventas by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 12,988,943 shares of the real estate investment trust's stock worth $1,001,447,000 after buying an additional 475,633 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Ventas by 27.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,176,254 shares of the real estate investment trust's stock worth $710,060,000 after buying an additional 2,000,341 shares in the last quarter. Finally, Capital World Investors acquired a new stake in shares of Ventas during the fourth quarter worth approximately $594,116,000. 94.18% of the stock is currently owned by institutional investors.

Ventas Stock Down 0.7%

Shares of NYSE:VTR opened at $91.18 on Tuesday. Ventas, Inc. has a one year low of $66.38 and a one year high of $101.60. The company has a 50 day moving average of $92.58 and a 200-day moving average of $87.66. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.44 and a quick ratio of 0.44. The stock has a market cap of $46.77 billion, a price-to-earnings ratio of 168.85, a P/E/G ratio of 2.11 and a beta of 0.69.

Ventas (NYSE:VTR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Ventas had a net margin of 4.08% and a return on equity of 1.99%. The business had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same period in the prior year, the business posted $0.87 earnings per share. Ventas's revenue was up 21.7% compared to the same quarter last year. On average, sell-side analysts forecast that Ventas, Inc. will post 3.89 earnings per share for the current year.

Insider Activity at Ventas

In other Ventas news, Director Michael J. Embler bought 2,500 shares of the company's stock in a transaction on Wednesday, June 3rd. The stock was bought at an average price of $78.81 per share, for a total transaction of $197,025.00. Following the transaction, the director owned 19,202 shares of the company's stock, valued at approximately $1,513,309.62. The trade was a 14.97% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.53% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on VTR shares. Jefferies Financial Group boosted their target price on Ventas from $97.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, May 12th. Weiss Ratings raised Ventas from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, July 21st. Mizuho lifted their price objective on Ventas from $98.00 to $104.00 and gave the company an "outperform" rating in a research report on Wednesday, July 22nd. UBS Group boosted their price objective on Ventas from $85.00 to $93.00 and gave the stock a "neutral" rating in a research note on Monday, May 4th. Finally, Barclays increased their target price on Ventas from $99.00 to $102.00 and gave the stock an "equal weight" rating in a report on Monday. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Ventas has an average rating of "Moderate Buy" and a consensus price target of $98.17.

Ventas Profile

Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas' business model combines property ownership with active asset management and capital markets activity.

Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source